This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–5
Adult Patients
Paediatric Patients
No dose adjustments required in the elderly, patients with mild renal impairment (estimated CrCl >50 to ≤80 mL/min) and those with hepatic impairment1,2
Table 1 footnotes:
§ The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
║There is very limited experience with the use of ZAVICEFTA for more than 14 days.
* The dose of ZAVICEFTA in patients with estimated CrCL ≤50 mL/min should be adjusted according to recommended doses. CrCL estimated using the Cockcroft-Gault formula.
† To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
‡ To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
Table 2 footnotes:
* CrCL estimated using the Cockcroft-Gault formula.
† Dose recommendations are based on pharmacokinetic modelling.
‡ Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis.
§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only.
Abbreviations
cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance; PK/PD, pharmacokinetics/pharmacodynamics.
When treating for cIAI, cUTI, HAP/VAP or LTO, to be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
When treating for cIAI or LTO, to be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
Table 3 footnotes:
* CrCL estimated using the Schwartz bedside formula.
¶ The total treatment duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
ǁ There is very limited experience with the use of ZAVICEFTA for more than 14 days.
**There is limited experience with the use of ZAVICEFTA in paediatric patients 3 months to < 6 month.
Table 4 footnotes:
*CrCL estimated using the Schwartz bedside formula
† Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
**Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis
Table 5 footnotes:
*CrCL estimated using the Schwartz bedside formula
†Dose recommendations are based on pharmacokinetic modelling. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only
There is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73m2
ZAVICEFTA® (ceftazidime-avibactam): For the treatment of adult and paediatric patients aged 3 months and older at high risk of MDR Gram-negative infections1
Abbreviations
cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; LTO, limited treatment options; VAP, ventilator-associated pneumonia; AMR, Antimicrobial Resistance; PK/PD, pharmacokinetics/pharmacodynamics.
Prescribing information
Click here for Precribing Information for Zavicefta® (ceftazidime and avibactam)
Zyvox® (linezolid)
Zyvox (linezolid) 2mg/ml Solution for Infusion
Zyvox (linezolid) 600mg Film-Coated Tablets
Zyvox (linezolid) 100mg/5ml Granules for Oral Suspension
Daptomycin
Great Britain
Daptomycin 350mg Powder for solution for injection/infusion
Daptomycin 500mg Powder for solution for injection/infusion
Northern Ireland
Daptomycin 350 & 500mg powder for solution for injection/infusion
References
Federico Pea, Professor of Pharmacology at the University of Bologna, Italy, presents the 'PK/PD attributes of ceftazidime–avibactam in patients'.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021